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ABSTRACT. Objective. To evaluate the impact of 4
months of daily zinc supplementation on the incidence
of severe and recurrent diarrhea in children 6 to 30
months of age.
Methods. A double-blind, randomized, placebo-con-
trolled trial was conducted on children who were iden-
tified by a door-to-door survey to be aged 6 to 30 months
and residing in the urban slum of Dakshinpuri, New
Delhi. They were randomized to receive daily zinc glu-
conate (elemental zinc 10 mg to infants and 20 mg to
older children) or placebo. A field attendant adminis-
tered the syrup daily at home for 4 months except on
Sundays, when the mother did so. One bottle that con-
tained 250 mL was kept in the child’s home and replaced
monthly. Field workers visited households every seventh
day during the 4-month follow-up period. At each visit,
information was obtained for the previous 7 days on
history of fever, number and consistency of stools, and
presence of cough. When the child was ill, illness char-
acteristics and treatment seeking outside the home were
determined. If the child had diarrhea or vomiting, then
dehydration was assessed. At household visits, 2 packets
of oral rehydration salts were given when a child had
diarrhea. Children who visited the study clinic sponta-
neously for illness or were referred by the field workers
were treated according to the standard national program
guidelines. Antibiotics were advised only for diarrhea
with bloody stools or for associated illnesses. For using
generalized estimating equations for longitudinal analy-
sis of a recurring event such as diarrhea, the follow-up
data for each child was divided into 17 child-periods of 7
days each and presence or absence of an incident episode
of diarrhea or severe diarrhea within each 7-day period
was coded. This method of analysis does not assume
independence of events and therefore prevents underes-
timation of variance that results because of correlation of
morbidity within the same child. A logistic generalized
estimating equations model with exchangeable correla-
tion covariance-variance matrix was then used to esti-
mate the effect size.
Results. Zinc or placebo doses were administered on
88.8% and 91.2%, respectively, of study days during the 4
months of follow-up. There was a small but significant
increase in the average number of days with vomiting in
the zinc group (4.3 [standard deviation (SD): 5.8] vs 2.6
[SD 3.9] days; difference in means: 1.7 [95% confidence
interval (CI): 1.3–2.1] days). At the baseline, mean plasma
zinc was 62.0 g/dL (SD: 14.3 g/dL) in the zinc and 62.0
g/dL (SD: 11.2 g/dL) in the placebo group; 45.8% and
42%, respectively, had low plasma zinc levels below 60
g/dL. At the end of the study, plasma zinc levels were
substantially higher in the zinc group (ratio of geometric
means: 1.94 [95% CI: 1.86–2.03]) and the proportion with
low plasma zinc was lower (difference in proportions:
46.7% [95% CI: 41.8% to 51.4%]). The incidence of
diarrhea during follow-up was lower in the zinc-supple-
mented as compared with the placebo group (odds ratio
[OR]: 0.88; 95% CI: 0.82–0.95). The beneficial impact of
zinc was greater on the incidence of diarrhea with pro-
gressively increasing duration: episodes of diarrhea that
lasted 1 to 6 days (OR: 0.92; 95% CI: 0.85–1.00), 7 to 13
days (OR: 0.79; 95% CI: 0.65–0.95), and >14 days (OR:
0.69; 95% CI: 0.48–0.98). The impact was also greater on
the incidence of episodes with progressively higher stool
frequency: 3 to 5 stools per day (OR: 0.90; 95% CI: 0.83–
0.98), 6 to 9 stools per day (OR: 0.87; 95% CI: 0.77–0.98),
and >10 per day (OR: 0.77; 95% CI: 0.63–0.94). In the zinc
group, significantly more children experienced no diar-
rheal episode during the study period (risk ratio [RR]:
1.22; 95% CI: 1.02–1.44). Furthermore, substantially fewer
children (RR: 0.51; 95% CI: 0.36–0.73) experienced recur-
rent diarrhea, defined as >6 diarrheal episodes in the
follow-up period as compared with children in the pla-
cebo group. The number of children who were hospital-
ized for any cause tended to be lower in the zinc group,
but the difference was not statistically significant (1.79%
vs 2.43%; RR: 0.74; 95% CI: 0.43–1.27). The baseline mean
plasma copper (g/dL) was similar in the 2 groups (dif-
ference in means: 1.6; 95% CI: 2.9 to 6.1). The end study
plasma copper levels were significantly lower in the zinc
group (difference in means: 15.5; 95% CI: 19.9 to
11.1).
Conclusions. Zinc supplementation substantially re-
duced the incidence of severe and prolonged diarrhea,
the 2 important determinants of diarrhea-related mortal-
ity and malnutrition. This intervention also substantially
reduced the proportion of children who experienced re-
current diarrhea. Prompt measures to improve zinc status
of deficient populations are warranted. The potential
approaches to achieve this goal include food fortifica-
tion, dietary diversification, cultivation of plants that
are zinc dense or have a decreased concentration of
zinc absorption inhibitors, and supplementation of se-
lected groups of children. Future studies should assess
the impact of increased zinc intakes on childhood mor-
tality in developing countries. For facilitating inter-
vention, there is a need to obtain reliable estimates of
zinc deficiency, particularly in developing countries.
The functional consequences of the effect of various
doses of zinc on plasma copper levels merits additional
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Zinc deficiency is common in children in devel-oping countries because the overall food in-take as well as the consumption of animal
foods is low and the bioavailability of zinc from the
phytate-rich cereal-based diets is limited. Stool zinc
losses during recurrent diarrheal illnesses are also a
contributing factor.1
Zinc deficiency impairs innate as well as acquired
immunity.2,3 Zinc deficiency also has direct effects on
the gastrointestinal tract that lead to an increased
clinical severity of acute enteric infections.4,5
Reduced diarrheal morbidity has been docu-
mented in zinc supplementation trials,6 but these
were not large enough to assess impact on clinically
severe illness. Before public health policy is made, it
is important to assess whether zinc supplementation
prevents clinically severe and recurrent diarrhea.
The clinical features associated with greater severity
and risk of death during diarrheal illnesses include
high stool frequency or stool output and duration of
14 or more days.7,8 A significant reduction in the
incidence of such severe episodes would justify
adoption of measures to prevent zinc deficiency in
susceptible populations. We therefore evaluated the
impact of daily zinc supplementation in a represen-
tative sample of children who were aged 6 to 30
months and enrolled from a New Delhi slum area,
with a sample size sufficient to determine the impact
on the incidence of severe diarrhea.
METHODS
Study Setting
The trial was implemented in the urban slum of Dakshinpuri,
which comprises 15 000 dwellings and a population of approxi-
mately 75 000. Available data suggested that malnutrition and
zinc deficiency were common in early childhood.9,10 Approxi-
mately one fifth of children who were younger than 5 years were
wasted (weight-for-age z score below 2) and half were stunted
(height-for-age z score below 2). Subclinical zinc deficiency (se-
rum zinc 60 g/dL) was present in 37% of children who were
aged 12 to 59 months and brought for care for diarrhea in a
community clinic.9,10
Randomization Scheme and Blinding
A simple randomization scheme in blocks of 8 was generated
by a person at Statens Serum Institut, who was not involved in the
field work or the data analysis, using the SAS software (version
8.1; SAS Institute, Cary, NC). The zinc and placebo syrups were
prepared and packaged in unbreakable bottles by GK Pharma ApS
(Køge, Denmark), which also labeled the bottles with unique
identification numbers according to the randomization code. The
zinc and placebo syrups were similar in appearance, taste, and
packaging.
Enrollment and Intervention Delivery
Enrollment began on February 15, 1998. In a door-to-door sur-
vey, 3802 children who were 6 to 30 months of age were identified.
Enrollment required that the parent(s) give informed consent and
that the families did not intend to emigrate (Fig 1). Exclusion
criteria included refusal of consent, likely to move out of the study
area within the next 4 months, requiring urgent hospitalization on
the scheduled enrollment day, or having received vitamin A
within the previous 2 months. The last exclusion criterion was
adopted to avoid toxicity, because all included subjects were given
a massive dose of vitamin A (100 000 IU to infants and 200 000 IU
to older children) at enrollment in addition to zinc or placebo as
required by the national program policy. The 2482 enrolled chil-
dren were randomized to receive zinc gluconate (10 mg of ele-
mental zinc/d to infants and 20 mg/d to older children) or pla-
cebo daily for a period of 4 months. The follow-up of the last child
was completed on September 30, 2000.
We chose twice the recommended dietary allowance for sup-
plementation in this study to allow for possible impairment in
absorption of ingested zinc among children as a result of con-
sumption of a predominantly phytate-rich cereal-based diet, bac-
terial overgrowth, and protozoal or parasitic infestations. A higher
intake may also be required to compensate for excessive losses of
zinc during the diarrheal illnesses that are common in this set-
ting.1
A field attendant administered the syrup daily at home for 4
months except on Sundays, when the mother was asked to ad-
minister it. One bottle that contained 250 mL was kept in the
child’s home and replaced monthly.
The study was approved by the ethics committee of the All
India Institute of Medical Sciences. Informed written consent was
obtained from the community leaders. Details of the study were
given in writing and also read aloud to the parents in the presence
of a witness. Signatures or thumb impressions were obtained on a
consent form, and a copy of the document was left with the family.
Trial Size Calculations
Trial size was estimated using information from earlier studies
in the same population,11 which reported a diarrhea incidence of
6 episodes/child/y. For detecting a 15% reduction in diarrhea
incidence, 996 children were required per group for the 4-month
follow-up period. For detecting a 25% reduction in the incidence
of diarrhea with a duration of 7 or more days and a similar
reduction in episodes with 10 stools per day, 1100 and 1050
children per group, respectively, were required with the same
study duration. The value of  was taken as 0.05 (95% confidence)
and that of  as 0.1 (90% power) for these calculations. To allow for
approximately a 10% attrition rate, we enrolled approximately
1240 children per group.
Outcomes and Their Measurement
Field workers visited households every seventh day during the
4-month follow-up period. At each visit, information was obtained
for the previous 7 days on history of fever, number and consis-
tency of stools, and presence of cough. When the child was ill,
illness characteristics and treatment seeking outside the home
were determined. If the child had diarrhea or vomiting, then
dehydration was assessed. Growth was assessed through weight
and length measurements at enrollment and at the end of the
study using Seca Salter Scales and locally manufactured infantom-
eters that read to the nearest 0.1 kg and 0.1 cm, respectively.
At household visits, 2 packets of oral rehydration salts were
given when a child had diarrhea. At enrollment, caregivers were
informed that clinical services for their children would be avail-
able at the study clinic established in the community. Children
who visited the clinic spontaneously or sick children who were
referred to the clinic by field workers were treated according to the
World Health Organization guidelines for Integrated Manage-
ment of Childhood Illnesses.12
Plasma Zinc
At enrollment, nonfasting venous blood (approximately 5 mL)
was drawn in zinc-free heparinized polypropylene tubes
(Sarstedt, Nu¨mbrecht, Germany) between 9 am and 4 pm by 1 of
the physicians. The heparinized blood was centrifuged, and
plasma was transferred to zinc-free polypropylene vials (Eppen-
dorf, Hinz, Germany), which were stored at 20°C until analysis.
In a randomly selected 30% subsample, a second blood sample
was taken at the end of the study to assess the compliance as
reflected by a change in plasma zinc concentration. Approxi-
mately half of the plasma specimens were analyzed for zinc using
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a standard flame furnace atomic absorption spectrophotometer
technique (GBC Avanta, Dandenong, Victoria, Australia), and the
other half were assessed by inductively coupled plasma atomic
emission spectrometry (Ash IRIS/AP, Thermo Jarell, Franklin,
MA).13,14 Seronorm (Sero AS, Billingstad, Norway) was used as
the reference standard in every batch of 20 samples in both meth-
ods. The 2 methods were calibrated to give the same results before
initiating the analysis of study samples. Plasma copper was ana-
lyzed simultaneously with plasma zinc in the same sample by
inductively coupled plasma atomic emission spectrometry.14
Standardization and Quality Control
A study manual that described all operating procedures was
used during training and throughout the study. Standardization
exercises were conducted to achieve agreement within and be-
tween study personnel for questionnaire filling, assessment of
dehydration, and weight and length measurements. Retraining
exercises were conducted every 3 months.
Supervisors monitored the field workers’ activities. Indepen-
dent supervisory checks were made to inquire about daily dis-
pensing of the syrup (0.5% of total visits) and to verify the data
collected at morbidity visits (1% of total visits). Field workers were
also observed at home visits (1% of visits) for assessing the inter-
action with the family, assessment of dehydration, measurement
of temperature and lower chest indrawing, and so forth.
Data Management and Analysis
The data entry system with range and consistency checks was
designed using FoxPro for Windows (Microsoft Corporation, Red-
mond, WA). The data were double-entered independently by 2
data clerks. Data were entered and validated within 48 hours after
completion of the questionnaires in the field.
Diarrhea was defined as the passage of 3 or more liquid or
watery stools in a 24-hour period. Recovery was defined as the
first day of a 72-hour period when the child had no diarrhea.
Episodes of severe diarrhea were computed using 2 indicators of
severity: duration of episodes or the highest stool frequency on
any day of the episode. Recurrent diarrhea was defined as 6
diarrheal episodes during the 4-month study period. For using
generalized estimating equations (GEE) for longitudinal analysis,
the follow-up data for each child was divided into 17 child-periods
of 7 days each. This method of analysis does not assume indepen-
dence of events and therefore prevents underestimation of vari-
ance that results because of correlation of morbidity within the
same child. For a child-period to be included in the analysis, the
child had to contribute at least 50% (4 days) of the given 7-day
period. Presence or absence of an incident episode of diarrhea or
severe diarrhea within each 7-day period for a child was coded. A
logistic GEE model with exchangeable correlation covariance-vari-
ance matrix was then used to estimate the effect size. The propor-
Fig 1. Trial profile.
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tion of days of follow-up with diarrhea was calculated for each
child, and the mean prevalence in each group was estimated.
The distribution of the end-of-study plasma zinc in the zinc
group was not normal. Therefore, we log-transformed the plasma
zinc results in both the groups, and the effect size is presented as
the ratio of geometric means with their 95% confidence intervals
(CIs). Statistical analysis was performed using Stata, version 6
(Stata Corp, Union Station, TX). Blinding was also maintained
during analyses by coding the groups as A and B.
RESULTS
Baseline Characteristics
The children in the 2 groups were comparable for
a number of baseline characteristics, including age,
anthropometry, child feeding practices, maternal lit-
eracy, family size, morbidity in the previous 24
hours, and family socioeconomic characteristics (Ta-
ble 1). The flow diagram of study participants and
reasons for loss to follow-up is shown in Fig 1. Of
those randomized, 1093 (88.1%) children in the zinc
group and 1133 (91.3%) in the placebo group were
available at the last scheduled follow-up visit.
Plasma Zinc
The mean plasma zinc at baseline was 62 g/dL
(standard deviation [SD] 12.8). Approximately 44%
of children had plasma zinc concentration below 60
g/dL, and 27% had plasma zinc concentration be-
low 55 g/dL. The plasma zinc concentration was
significantly higher at the end of the study in the
zinc-supplemented children (ratio of geometric
means: 1.94; 95% CI: 1.86–2.03). The difference in
plasma zinc between end-of-study and baseline con-
centrations was also substantially higher in the zinc
group as compared with the placebo group (ratio of
geometric means: 2.0; 95% CI: 1.91–2.09; Table 2).
Acceptability and Side Effects
Zinc or placebo doses were administered on 88.8%
and 91.2%, respectively, of study days during the 4
months of follow-up. There was a small but signifi-
cant increase in the average number of days with
vomiting in the zinc group (4.3 [SD 5.8] vs 2.6 [SD
3.9] days; difference in means: 1.7; 95% CI: 1.3–2.1
days).
Eight children (0.3%), all in the zinc group, re-
ported vomiting immediately after the supplement
was given on each day during the first 2 weeks of
supplementation. As per a priori decision, they were
not supplemented any further. In none of these cases
was the vomiting severe or reported at times other
than immediately after administration of the supple-
ment.
Effect on Overall and Severe Diarrhea Incidence
There were 2794 episodes (7.7 episodes/child-
year) of diarrhea in the zinc group and 3165 (8.6
episodes/child-year) in the placebo group during the
follow-up period. Of these, 36 episodes in the zinc
group and 44 episodes in the placebo group occurred
in the same 7-day child-period and were therefore
ignored in the GEE analysis.
In the GEE logistic regression model, zinc supple-
mentation was associated with lower risk of diarrhea
(odds ratio [OR]: 0.88; 95% CI: 0.82–0.95). The bene-
ficial effect of zinc supplementation was greater on
diarrhea that lasted 7 to 13 days (OR: 0.79; 95% CI:
0.65–0.95) and on episodes that lasted 14 days (OR:
0.69; 95% CI: 0.48–0.98). The effect on incidence of
diarrhea with stool frequency of10 on any day was
also greater than that on all diarrhea in the zinc-
supplemented children (OR: 0.77; 95% CI: 0.63–0.94;
Table 2). The mean prevalence of diarrhea per 100
days of follow-up was 6.6 in the zinc group and 7.9
in the placebo group (difference in means: 1.30;
95% CI: 0.61 to 2.0).
Effect on Recurrent Diarrhea
In a child-based analysis, more children in the
zinc-supplemented group experienced no episodes
of diarrhea during the study period than those in the
placebo group (risk ratio [RR]: 1.22; 95% CI: 1.02–
1.44). Furthermore, substantially fewer children had
recurrent diarrhea, defined as experiencing 6 diar-
rheal episodes during the study period in the zinc-
supplemented group than those given placebo (RR:
0.51; 95% CI: 0.36–0.73; Table 3). The number of
children who were hospitalized as a result of any
cause tended to be lower in the zinc group, but the
difference was not statistically significant (1.79% vs
2.43%; RR: 0.74; 95% CI: 0.43–1.27). Three children,
all in the placebo group, died.
TABLE 1. Baseline Characteristics of Children Who Were Aged 6 to 30 Months and Enrolled in the Zinc and Placebo Groups*
Characteristic Zinc Group
(n  1228)
Placebo Group
(n  1236)
Age (mo) at enrollment (mean [SD]) 15.6 (7.5) 15.0 (7.5)
Male 610 (49.7) 679 (54.9)
Breastfed 849 (69.1) 861 (69.7)
24-h prevalence
Cough 369 (30.0) 375 (30.3)
Fever 104 (8.5) 91 (7.4)
Fast breathing 56 (4.6) 54 (4.4)
Reported diarrhea 141 (11.5) 153 (12.4)
Literate mother 798 (65.1) 785 (64.3)
Family income (Rupees) per year (median [IQR]) 36 000 (24 000, 54 000) 36 000 (24 000, 54 000)
Weight (mean [SD]) 8.1 (1.6) 8.0 (1.6)
Length/height (mean [SD]) 73.0 (7.1) 72.4 (7.2)
IQR indicates interquartile range.
* All values are number (%) except those marked mean (SD) or median (IQR).
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Effect on Incidence of Diarrhea and Severe Diarrhea in
Subgroups
There was a trend toward lower incidence of diar-
rhea and severe diarrhea in the zinc group in all
subgroups examined (Fig 2). The reductions were
significant only in children who had plasma zinc60
g/dL, were 12 months or older, and were not
wasted or stunted. The number of children was rel-
atively larger in these subgroups and may partly
explain the narrower CIs.
Effect on Plasma Copper
The children in the 2 groups were comparable for
mean copper levels at baseline (Table 4). At the end
of the study, the mean copper levels were substan-
tially lower in the zinc group (difference in means:
15.5 g/dL; 95% CI: 19.9 to 11.1). The propor-
tion of children at the end of the study who had
plasma copper 80 g/dL was 4.8% in the zinc
group compared with 0.6% in the placebo group
(difference in proportions: 4.2%; 95% CI: 2%–6.2%).15
DISCUSSION
Daily zinc supplementation of infants and young
children in a representative sample from a popula-
tion with low socioeconomic status reduced the odds
by 12% for all diarrheal illnesses, 23% for diarrheal
episodes with very high stool frequency, and 31% for
persistent diarrheal episodes. In acute infectious en-
teritis among children, stool frequency of 10 or more
is associated with a high risk of complications,16 and
diarrheal episode duration is strongly associated
with the risk of death. In a north Indian cohort study,
the case fatality ratio for diarrheal episodes that
lasted 14 days (11.94%) was several times higher
than for episodes that lasted 7 to 13 days (0.8%) or7
days (0.6%).7
Zinc supplementation also resulted in a substantial
decline in the proportion of children who experi-
enced recurrent diarrhea, suggesting that zinc defi-
ciency may be an important underlying factor. Pre-
vious studies have shown that in developing
countries, diarrheal morbidity has a skewed distri-
bution and a subset of children experience exception-
ally high diarrhea morbidity that is not explained by
socioeconomic factors or anthropometric status.16
The impact on recurrent diarrhea has important im-
plications, as recurrent diarrhea is an established risk
factor for malnutrition.17,18
The baseline plasma copper levels were substan-
tially above the upper limit of the range for young
children; this may be related to the use of brass
utensils in the study households or may be a mani-
festation of an acute-phase response to infections,
common in this setting. The lower, end-of-study cop-
per levels in the intervention group may be attribut-
able to the effect of zinc on copper absorption19,20 or
decreased prevalence of infections at the time of
measurement of end-of-study plasma copper and
therefore lesser proportion of children with an acute-
phase response. The functional consequences of the
effect of various doses of zinc on plasma copper
levels merits additional study.
When the current and other available studies are
viewed together, the preventive impact of zinc sup-
plementation against diarrhea does not seem to be
TABLE 2. Zinc and Copper Concentrations at Baseline and End of Study in Zinc-Supplemented and Placebo-Group Children
Zinc
Group
(n  1210)
Placebo
Group
(n  1221)
Difference in Means or
Difference in Proportions
(95% CI)
Baseline
Plasma zinc (g/dL; mean [SD]) 62.0 (14.3) 62.0 (11.2) 0 (1.0 to 1.0)
60 (g/dL; n [%]) 553 (45.8%) 513 (42.0%) 3.8% (0.3% to 7.6%)
n  478) (n  472)
Plasma copper (g/dL; mean [SD]) 166.8 (33.3) 165.2 (37.3) 1.6 (2.9 to 6.1)
End of study (n  450) (n  499)
Plasma zinc (g/dL; mean [SD]) 129.1 (66.3) 60.8 (13.8) 68.3 (62.3–74.2)
60 (g/dL; n [%]) 21 (4.6%) 256 (51.3%) 46.7% (41.8% to51.4%)
(n  440) (n  490)
Plasma copper (g/dL; mean [SD]) 140.4 (36.5) 155.9 (31.6) 15.5 (19.9 to 11.1)
TABLE 3. Impact of Zinc Supplementation on the Incidence of All and Severe Diarrhea Corrected for Correlation of Episodes
Occurring in the Same Child by GEE Logistic Regression Models Analysis
Zinc
(n  1228)
Placebo
(n  1236)
OR
(95% CI)
Total child-years of follow-up 361.7 368.2
Number of 7-d child-periods with 4 d of follow-up 18 841 19 179
Child-periods with an incident episode of diarrhea 2758 3121 0.88 (0.82–0.95)
Child-periods with an incident diarrhea episode lasting
1–6 d 2348 2567 0.92 (0.85–1.00)
7–13 d 243 312 0.79 (0.65–0.95)
14 d 52 77 0.69 (0.48–0.98)
Child-periods with an incident diarrhea episode with
maximum stools/d
3–5 2204 2453 0.90 (0.83–0.98)
6–9 791 918 0.87 (0.77–0.98)
10 235 310 0.77 (0.63–0.94)
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restricted to those with wasting, stunting, or low
plasma zinc. This makes it difficult to select a target
group on whom the intervention may be focused.
The limitations of plasma zinc as a measure of zinc
status may partly explain these findings.12 Alterna-
tively, the impact of zinc may not be attributable only
to correction of deficiency, ie, there may be some
pharmacologic effect even in those with normal zinc
status.21
Prevention of diarrhea by optimizing zinc intakes
is biologically plausible. The low mean plasma zinc
shows that deficiency was common in the trial sub-
jects. In experimental models, zinc deficiency has
been shown to impair cellular and humoral immune
function.3,22 Supplementation in such individuals
improves immune function, including delayed cuta-
neous hypersensitivity, and increases the number of
CD4 (helper) lymphocytes.3 Zinc deficiency also has
direct effects on the gastrointestinal tract, such as
impaired intestinal brush border, increased secretion
in response to bacterial enterotoxins, and perturba-
tions in intestinal permeability.4,23 Finally, zinc in the
treatment of acute diarrhea has been shown consis-
tently to reduce episode duration and severity.24
An important strength of the study design is that
subjects of the present trial constituted a representa-
tive sample of a well-defined, low-income urban
community. The findings of the study are therefore
generalizable to low-income populations with simi-
lar dietary habits and morbidity patterns. Although
we did not include children who were younger than
6 months, recent reports of a mortality decline in
zinc-supplemented 1- to 9-month-old small-for-ges-
tational-age infants suggests likely benefits on mor-
bidity in early infancy as well, particularly in coun-
tries where low birth weight is common.25
The findings of the current and previous studies
suggest that improving zinc status in deficient pop-
ulations is expected to reduce substantially diarrheal
and respiratory morbidity.6,24 For facilitating inter-
vention, there is a need to obtain reliable estimates of
zinc deficiency, particularly in developing countries.
Prompt measures to improve zinc status of deficient
populations are warranted. The potential approaches
to achieve this goal include food fortification, dietary
diversification, cultivation of plants that are zinc
dense or have a decreased concentration of zinc ab-
sorption inhibitors, and supplementation of selected
groups of children. Future studies should assess the
impact of increased zinc intakes on childhood mor-
tality in developing countries.
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